• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

β-葡萄糖-1,6-二磷酸在体外稳定病理性磷酸甘露糖变位酶 2 突变体,是开发最常见糖基化疾病 PMM2-CDG 的药理学伴侣的先导化合物。

β-Glucose-1,6-Bisphosphate Stabilizes Pathological Phophomannomutase2 Mutants In Vitro and Represents a Lead Compound to Develop Pharmacological Chaperones for the Most Common Disorder of Glycosylation, PMM2-CDG.

机构信息

Dipartimento di Biologia, Università Federico II, 80126 Napoli, Italy.

Dipartimento di Scienze e Tecnologie Ambientali, Biologiche e Farmaceutiche, Università degli Studi della Campania "Luigi Vanvitelli", 81100 Caserta, Italy.

出版信息

Int J Mol Sci. 2019 Aug 26;20(17):4164. doi: 10.3390/ijms20174164.

DOI:10.3390/ijms20174164
PMID:31454904
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6747070/
Abstract

A large number of mutations causing PMM2-CDG, which is the most frequent disorder of glycosylation, destabilize phosphomannomutase2. We looked for a pharmacological chaperone to cure PMM2-CDG, starting from the structure of a natural ligand of phosphomannomutase2, α-glucose-1,6-bisphosphate. The compound, β-glucose-1,6-bisphosphate, was synthesized and characterized via P-NMR. β-glucose-1,6-bisphosphate binds its target enzyme in silico. The binding induces a large conformational change that was predicted by the program PELE and validated in vitro by limited proteolysis. The ability of the compound to stabilize wild type phosphomannomutase2, as well as frequently encountered pathogenic mutants, was measured using thermal shift assay. β-glucose-1,6-bisphosphate is relatively resistant to the enzyme that specifically hydrolyses natural esose-bisphosphates.

摘要

大量导致 PMM2-CDG 的突变使磷酸甘露糖变位酶 2 不稳定,PMM2-CDG 是最常见的糖基化紊乱。我们从磷酸甘露糖变位酶 2 的天然配体α-葡萄糖-1,6-双磷酸的结构出发,寻找一种治疗 PMM2-CDG 的药理学伴侣。通过 P-NMR 合成并表征了化合物β-葡萄糖-1,6-双磷酸。该化合物在计算机中与靶酶结合。该结合诱导了一个大的构象变化,该变化由程序 PELE 预测,并通过有限的蛋白水解在体外验证。通过热移位测定测量了该化合物稳定野生型磷酸甘露糖变位酶 2 以及常见致病性突变体的能力。β-葡萄糖-1,6-双磷酸对专门水解天然己糖-双磷酸的酶具有相对抗性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e788/6747070/f6c08e0279f4/ijms-20-04164-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e788/6747070/13181342b30b/ijms-20-04164-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e788/6747070/2ee7f044887b/ijms-20-04164-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e788/6747070/2b4f140f9fca/ijms-20-04164-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e788/6747070/c6afd0863a1f/ijms-20-04164-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e788/6747070/47083a62f890/ijms-20-04164-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e788/6747070/a6f82cbee537/ijms-20-04164-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e788/6747070/f6c08e0279f4/ijms-20-04164-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e788/6747070/13181342b30b/ijms-20-04164-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e788/6747070/2ee7f044887b/ijms-20-04164-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e788/6747070/2b4f140f9fca/ijms-20-04164-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e788/6747070/c6afd0863a1f/ijms-20-04164-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e788/6747070/47083a62f890/ijms-20-04164-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e788/6747070/a6f82cbee537/ijms-20-04164-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e788/6747070/f6c08e0279f4/ijms-20-04164-g007.jpg

相似文献

1
β-Glucose-1,6-Bisphosphate Stabilizes Pathological Phophomannomutase2 Mutants In Vitro and Represents a Lead Compound to Develop Pharmacological Chaperones for the Most Common Disorder of Glycosylation, PMM2-CDG.β-葡萄糖-1,6-二磷酸在体外稳定病理性磷酸甘露糖变位酶 2 突变体,是开发最常见糖基化疾病 PMM2-CDG 的药理学伴侣的先导化合物。
Int J Mol Sci. 2019 Aug 26;20(17):4164. doi: 10.3390/ijms20174164.
2
Heterodimerization of Two Pathological Mutants Enhances the Activity of Human Phosphomannomutase2.两种病理突变体的异源二聚化增强了人类磷酸甘露糖异构酶2的活性。
PLoS One. 2015 Oct 21;10(10):e0139882. doi: 10.1371/journal.pone.0139882. eCollection 2015.
3
Conformational response to ligand binding in phosphomannomutase2: insights into inborn glycosylation disorder.磷酸甘露糖变位酶2中配体结合的构象反应:对先天性糖基化障碍的见解
J Biol Chem. 2014 Dec 12;289(50):34900-10. doi: 10.1074/jbc.M114.586362. Epub 2014 Oct 16.
4
Proteostasis regulators as potential rescuers of PMM2 activity.蛋白稳态调节剂作为 PMM2 活性的潜在挽救剂。
Biochim Biophys Acta Mol Basis Dis. 2020 Jul 1;1866(7):165777. doi: 10.1016/j.bbadis.2020.165777. Epub 2020 Mar 25.
5
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.将醛糖还原酶抑制剂和糖尿病周围神经病变药物依帕司他用于先天性糖基化缺陷症 PMM2-CDG。
Dis Model Mech. 2019 Nov 11;12(11):dmm040584. doi: 10.1242/dmm.040584.
6
Pharmacological Chaperoning: A Potential Treatment for PMM2-CDG.药理学伴侣疗法:一种治疗PMM2-CDG的潜在方法。
Hum Mutat. 2017 Feb;38(2):160-168. doi: 10.1002/humu.23138. Epub 2016 Nov 21.
7
The Effects of PMM2-CDG-Causing Mutations on the Folding, Activity, and Stability of the PMM2 Protein.导致PMM2-CDG的突变对PMM2蛋白折叠、活性及稳定性的影响
Hum Mutat. 2015 Sep;36(9):851-60. doi: 10.1002/humu.22817. Epub 2015 Jul 23.
8
New and potential strategies for the treatment of PMM2-CDG.治疗庞贝病 2 型的新策略和潜在策略。
Biochim Biophys Acta Gen Subj. 2020 Nov;1864(11):129686. doi: 10.1016/j.bbagen.2020.129686. Epub 2020 Jul 23.
9
Hypolipidaemia among patients with PMM2-CDG is associated with low circulating PCSK9 levels: a case report followed by observational and experimental studies.庞贝病患者的血脂降低与循环 PCSK9 水平降低有关:病例报告及观察性和实验性研究。
J Med Genet. 2020 Jan;57(1):11-17. doi: 10.1136/jmedgenet-2019-106102. Epub 2019 Aug 7.
10
Liposome-encapsulated mannose-1-phosphate therapy improves global N-glycosylation in different congenital disorders of glycosylation.脂质体包裹的甘露糖-1-磷酸疗法可改善不同先天性糖基化障碍中的整体N-糖基化。
Mol Genet Metab. 2024 Jun;142(2):108487. doi: 10.1016/j.ymgme.2024.108487. Epub 2024 May 7.

引用本文的文献

1
Analysis of Phosphomannomutase-2 Dimer Interface Stability and Heterodimerization with Phosphomannomutase-1.磷酸甘露糖异构酶-2二聚体界面稳定性及与磷酸甘露糖异构酶-1异源二聚化的分析
Molecules. 2025 Jun 15;30(12):2599. doi: 10.3390/molecules30122599.
2
A comprehensive update of genotype-phenotype correlations in PMM2-CDG: insights from molecular and structural analyses.磷酸甘露糖变位酶2缺陷型先天性糖基化异常(PMM2-CDG)中基因型-表型相关性的全面更新:来自分子和结构分析的见解
Orphanet J Rare Dis. 2025 Apr 30;20(1):207. doi: 10.1186/s13023-025-03669-5.
3
AAV-based gene replacement therapy prevents and halts manifestation of abnormal neurological phenotypes in a novel mouse model of PMM2-CDG.

本文引用的文献

1
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.将醛糖还原酶抑制剂和糖尿病周围神经病变药物依帕司他用于先天性糖基化缺陷症 PMM2-CDG。
Dis Model Mech. 2019 Nov 11;12(11):dmm040584. doi: 10.1242/dmm.040584.
2
AZATAX: Acetazolamide safety and efficacy in cerebellar syndrome in PMM2 congenital disorder of glycosylation (PMM2-CDG).AZATAX:乙酰唑胺在 PMM2 先天性糖基化障碍(PMM2-CDG)小脑综合征中的安全性和疗效。
Ann Neurol. 2019 May;85(5):740-751. doi: 10.1002/ana.25457. Epub 2019 Mar 22.
3
Identification and characterization of phytocannabinoids as novel dual PPARα/γ agonists by a computational and in vitro experimental approach.
在一种新型的PMM2-CDG小鼠模型中,基于腺相关病毒的基因替代疗法可预防并阻止异常神经表型的显现。
Gene Ther. 2025 May;32(3):246-254. doi: 10.1038/s41434-025-00525-w. Epub 2025 Mar 17.
4
AAV9-based gene replacement augments PMM2 expression and improves glycosylation in primary fibroblasts of patients with phosphomannomutase 2 deficiency (PMM2-CDG).基于腺相关病毒9型(AAV9)的基因替代可增强磷酸甘露糖变位酶2缺乏症(PMM2-CDG)患者原代成纤维细胞中PMM2的表达并改善糖基化。
Mol Genet Metab Rep. 2023 Dec 16;38:101035. doi: 10.1016/j.ymgmr.2023.101035. eCollection 2024 Mar.
5
Congenital disorders of glycosylation: narration of a story through its patents.先天性糖基化障碍:从专利角度讲述一个故事。
Orphanet J Rare Dis. 2023 Aug 29;18(1):247. doi: 10.1186/s13023-023-02852-w.
6
Tracer metabolomics reveals the role of aldose reductase in glycosylation.示踪代谢组学揭示醛糖还原酶在糖基化中的作用。
Cell Rep Med. 2023 Jun 20;4(6):101056. doi: 10.1016/j.xcrm.2023.101056. Epub 2023 May 30.
7
[Advances in the diagnosis and treatment of phosphomannomutase 2 deficiency].[磷酸甘露糖变位酶2缺乏症的诊断与治疗进展]
Zhongguo Dang Dai Er Ke Za Zhi. 2023 Feb 15;25(2):223-228. doi: 10.7499/j.issn.1008-8830.2209049.
8
Evolutionary rescue of phosphomannomutase deficiency in yeast models of human disease.磷酸甘露糖变位酶缺乏症在人类疾病酵母模型中的进化拯救。
Elife. 2022 Oct 10;11:e79346. doi: 10.7554/eLife.79346.
9
Systematic Review: Drug Repositioning for Congenital Disorders of Glycosylation (CDG).系统评价:糖基化先天性疾病(CDG)的药物重定位。
Int J Mol Sci. 2022 Aug 5;23(15):8725. doi: 10.3390/ijms23158725.
10
Nutrition interventions in congenital disorders of glycosylation.先天性糖基化障碍的营养干预措施。
Trends Mol Med. 2022 Jun;28(6):463-481. doi: 10.1016/j.molmed.2022.04.003. Epub 2022 May 10.
通过计算和体外实验方法鉴定和表征植物大麻素作为新型双重 PPARα/γ激动剂。
Biochim Biophys Acta Gen Subj. 2019 Mar;1863(3):586-597. doi: 10.1016/j.bbagen.2019.01.002. Epub 2019 Jan 3.
4
Yeast Models of Phosphomannomutase 2 Deficiency, a Congenital Disorder of Glycosylation.磷酸甘露糖变位酶2缺乏症的酵母模型,一种先天性糖基化障碍疾病
G3 (Bethesda). 2019 Feb 7;9(2):413-423. doi: 10.1534/g3.118.200934.
5
The Analysis of Variants in the General Population Reveals That Is Extremely Tolerant to Missense Mutations and That Diagnosis of PMM2-CDG Can Benefit from the Identification of Modifiers.在普通人群中分析变异体表明, 对错义突变具有极强的耐受性,并且 PMM2-CDG 的诊断可以受益于修饰因子的鉴定。
Int J Mol Sci. 2018 Jul 30;19(8):2218. doi: 10.3390/ijms19082218.
6
CDG Therapies: From Bench to Bedside.CDG 疗法:从基础研究到临床应用。
Int J Mol Sci. 2018 Apr 27;19(5):1304. doi: 10.3390/ijms19051304.
7
A mutant of phosphomannomutase1 retains full enzymatic activity, but is not activated by IMP: Possible implications for the disease PMM2-CDG.磷酸甘露糖变位酶1的一种突变体保留了完整的酶活性,但不受肌苷酸(IMP)激活:对疾病磷酸甘露糖变位酶2缺陷型先天性糖基化障碍(PMM2-CDG)的潜在影响
PLoS One. 2017 Dec 19;12(12):e0189629. doi: 10.1371/journal.pone.0189629. eCollection 2017.
8
SDM: a server for predicting effects of mutations on protein stability.SDM:一种用于预测突变对蛋白质稳定性影响的服务器。
Nucleic Acids Res. 2017 Jul 3;45(W1):W229-W235. doi: 10.1093/nar/gkx439.
9
Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease.在人溶酶体α-半乳糖苷酶上鉴定出变构结合位点,为法布里病的新型药理伴侣分子开辟了道路。
PLoS One. 2016 Oct 27;11(10):e0165463. doi: 10.1371/journal.pone.0165463. eCollection 2016.
10
Pharmacological Chaperoning: A Potential Treatment for PMM2-CDG.药理学伴侣疗法:一种治疗PMM2-CDG的潜在方法。
Hum Mutat. 2017 Feb;38(2):160-168. doi: 10.1002/humu.23138. Epub 2016 Nov 21.